AbbVie Inc. (NYSE:ABBV) is considered one of the 7 most undervalued pot stocks to buy by analysts. The company updated its 2025 earnings guidance to reflect a pre-tax acquired in-process research and development (IPR&D) expense of $823 million in the second quarter, impacting EPS. This expense is part of AbbVie’s strategy to enhance its pipeline through acquisitions and collaborations.

The $823 million IPR&D expense incurred by AbbVie is related to acquired research and development activities, typically arising from collaborations and acquisitions. These costs are not regularly forecasted due to their unpredictable timing and nature. AbbVie’s focus on bolstering its pipeline through strategic partnerships and acquisitions is reflected in this expense.

AbbVie Inc. is a diversified healthcare company with ties to the cannabis industry through products like Marinol, a synthetic THC treatment. The company holds patents related to cannabis for various medical uses, including cancer treatment, juvenile arthritis, and skin disorders. While AbbVie shows promise as an investment, other AI stocks may offer greater potential with lower risks.

Investors looking for undervalued AI stocks may find better opportunities elsewhere. AbbVie’s connection to the cannabis industry and healthcare sector may be overshadowed by other investment options. For those interested in AI stocks with significant potential amid current economic trends, explore our report on the best short-term AI stock for insights.

Read more at Yahoo Finance: AbbVie (ABBV) Updates 2025 EPS Guidance with $823M IPR&D Expense